Guest: Howard (Jack) West, MD

Chemoimmunotherapy has become more prevalent as a first-line treatment option for patients with non-small cell lung cancer (NSCLC). However, by compressing two therapies into one, we could be left with fewer alternatives if patients progress. Dr. Howard Jack West exposes these potential challenges and offers his perspective on second-line approaches in NSCLC care.

Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.